SUZHOU, China--(BUSINESS WIRE)--Suzhou-based MabSpace Biosciences announced that the preclinical data for its lead program MSB2311, a 2nd generation humanized PD-L1 blocking antibody with a unique pH-dependent antigen binding property, will be presented at the upcoming 2017 Inaugural American Society of Clinical Oncology (ASCO)-Society for Immunotherapy of Cancer （SITC） Annual Meeting on February 23rd-25th, 2017 in Orlando, Florida, US. The data provide a body of evidence that MSB2311 has significantly higher activities in inducing complete responses in humanized syngeneic tumor models than existing PD-L1 antibodies on the market at both low and high doses. MSB2311 has the potential of being a best-in-class PD-L1 antibody in achieving better efficacy and safety profile with lower doses required.
MabSpace is scheduled to present a poster on Thursday, February 23rd with the title of “Characterization of a Humanized PD-L1 Blocking Antibody with pH-Dependent Antigen Binding in a Humanized Syngeneic Tumor Model” by Qian et al., Abstract 177907, Poster #81, Board C10, 11:30-1:00 PM & 5:30PM-6:30 PM.
“Developing well-differentiated, lifesaving and highly affordable therapeutics is our mission. Using our proprietary immune tolerance breaking technology we generated a novel antibody with pH-dependent PD-L1 binding that can recycle within the tumor,” commented Xueming Qian, Ph.D., Founder, Chairman and CEO, MabSpace Biosciences. “This differentiated property of MSB2311 presents an opportunity to provide cancer patients with an agent of better efficacy and safety profile than existing PD-L1 antibodies yet highly affordable. We are honored to be selected for presentation and look forward to sharing our data at this inaugural ASCO-SITC meeting.”
MabSpace plans to start FIH study for MSB2311 later this year. MSB2311 is the first therapeutic antibody in its pipeline which consists of a panel of antibodies targeting various components of the tumor microenvironment, including both antagonistic and agonist antibodies. MabSpace plans to move two antibody programs to IND filing each year. These agents will allow MabSpace to develop its proprietary combinations for the treatment of cancer. MabSpace will focus on the development in China and find partners for ex-China development of these agents.
MabSpace Biosciences is a biotechnology company focused on the discovery and development of antibody therapeutics for oncology and fibrotic disorders leveraging its immune tolerance breaking technology (IMBT)-based antibody discovery platform and translational sciences capability. This technology enables the generation of antibodies with diverse target binding epitopes and well differentiated properties. MabSpace is headquartered in BioBay, Suzhou Industrial Park, China and has an R&D facility with fully-integrated in vitro and in vivo pharmacology profiling capabilities. Visit http://www.mabspacebio.com for more information.